Features of the selection of pathogenetic therapy in an elderly, comorbid patient with Crohn's disease

Larisa V. Tarasova , Nadezhda Yu. Kucherova , Daria A. Ivanova , Julia V. Tsyganova

For citation:

Abstract

The article describes a clinical case and the importance of selecting pathogenetic therapy in an elderly comorbid patient with inflammatory bowel disease – Crohn's disease.
Keywords: inflammatory bowel diseases, Crohn's disease, glucocorticoids, nonsteroidal anti-inflammatory drugs, cytostatics, monoclonal antibodies.

References

1. Zhao M, Gonczi L, Lakatos PL, Burisch J. The burden of inflammatory bowel disease in Europe in 2020. J Crohns Colitis. 2021;15(9):1573-87. DOI: 10.1093/ecco-jcc/jjab029

2. Cross RK, Wilson KT and Binion DG. Polypharmacy and Crohn’s disease. Alimentary Pharmacol & Therapeutics. 2005;21:1211-1216. DOI: 10.1111/j.1365-2036.2005.02429.x

3. Sheikh-Taha M, Asmar M. Polypharmacy and severe potential drug-drug interactions among older adults with cardiovascular disease in the United States. BMC Geriatr 2021;233. DOI: 10.1186/s12877-021-02183-0

4. Sergi G, De Rui M, Sarti S, Manzato E. Polypharmacy in the elderly: can comprehensive geriatric assessment reduce inappropriate medication use? Drugs Aging 2011;28(7):509-18. DOI: 10.2165/11592010-000000000-00000.

5. Wang J, Nakamura TI, Tuskey AG, Behm BW. Polypharmacy is a risk factor for disease flare in adult patients with ulcerative colitis: a retrospective cohort study. Intest Res 2019;17(4):496-503. DOI: 10.5217/ir.2019.00050

6. Mosli MH, Alsahafi M, Alsanea MN et al. Multimorbidity among inflammatory bowel disease patients in a tertiary care center: a retrospective study. BMC Gastroenterol 2022:487. DOI: 10.1186/s12876-022-02578-2

7. Bauerle KT, Harris C. Glucocorticoids and Diabetes. Mo Med 2016 Sep-Oct;113(5):378-83.

8. Kuo T, McQueen A, Chen TC, Wang JC. Regulation of Glucose Homeostasis by Glucocorticoids. Adv Exp Med Biol 2015;872:99-126. DOI: 10.1007/978-1-4939-2895-8_5

9. Селимов А.Ю., Елисеева Л.Н., Куринная В.П., Оранский С.П. Нарушения обмена глюкозы у пациентов, принимающих глюкокортикостероиды: особенности клинических проявлений и коррекции. Кубанский научный медицинский вестник. 2019;26(1):209-218. Selimov A.Yu., Eliseeva L.N., Kurinnaya V.P., Oransky S.P. Glucose metabolism disorders in patients taking glucocorticosteroids: features of clinical manifestations and correction. Kuban Scientific Medical Bulletin. 2019;26(1):209-218 (in Russian).

10. Ghassemi F, Ardeshir RA, Ahmadi G, Hoshmandi A. Azathioprine effects on kidney and liver in diabetic rats. World J Pharmaceutical research 2014;3(2):1559-67.

11. Ananthakrishnan AN, Higuchi LM, Huang ES et al. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Ann Intern Med 2012 Mar 6;156(5):350-359. DOI: 10.7326/0003-4819-156-5-201203060-00007

12. Xu XR, Liu CQ, Feng BS, Liu ZJ. Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease. World J Gastroenterol 2014 Mar 28;20(12):3255-64. DOI: 10.3748/wjg.v20.i12.3255

13. Meyer AM, Ramzan NN, Heigh RI, Leighton JA. Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs. Dig Dis Sci 2006;51(1):168-72. DOI: 10.1007/s10620-006-3103-5

14. Takeuchi K, Smale S, Premchand P et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006;4(2):196-202. DOI: 10.1016/s1542-3565(05)00980-8

15. Why NSAIDs Are Bad for Crohn’s and Ulcerative Colitis [Электронный ресурс]. – Режим доступа: https://www.verywellhealth.com/nsaids-non-steroidal-anti-inflammatories-and-ibd-1941656. Дата доступа: 16.09.2024.

16. Садыгова Г.Г. Внекишечные проявления воспалительных заболеваний кишечника: артропатии и артриты. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(6):101-105. DOI: 10.22416/1382-4376-2016-6-101-105. Sadygova G.G. Extra-intestinal manifestations of inflammatory bowel diseases: arthropathies and arthritis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(6):101-105. DOI: 10.22416/1382-4376-2016-6-101-105 (in Russian).

17. El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 2006;101(2):311-7. DOI: 10.1111/j.1572-0241.2006.00384.x

18. Mocci G, Tursi A, Onidi FM et al. Ustekinumab in the Treatment of Inflammatory Bowel Diseases: Evolving Paradigms. J Clin Med 2024;13(5):1519. DOI: 10.3390/jcm13051519

19. Gisbert JP, Chaparro M. Ustekinumab to treat Crohn’s disease. Gastroenterol y Hepatolog (English Edition) 2017;40(10):688-98. DOI: 10.1016/j.gastre.2017.08.003

For citation:Tarasova L.V., Kucherova N.Yu., Ivanova D.A., Tsyganova Yu.V. Features of the selection of pathogenetic therapy in an elderly comorbid patient with Crohn's disease. Clinical review for general practice. 2024; 5 (10): 19–22 (In Russ.). DOI: 10.47407/kr2024.5.10.00490

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice